Opus Genetics (IRD) Short term Debt (2019 - 2025)
Opus Genetics (IRD) reported Short term Debt of $21.3 million for Q3 2025, up 80.72% on a QoQ basis from $11.8 million in Q2 2025.
Opus Genetics (IRD) has 4 years of Short term Debt data on file, last reported at $21.3 million in Q3 2025.
- Quarterly Short term Debt changed N/A year-over-year to $21.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $21.3 million (changed N/A YoY) and the FY2019 annual result came in at $2.7 million, changed N/A from the prior year.
- Short term Debt climbed to $21.3 million in Q3 2025 per IRD's latest filing, from $11.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $21.3 million in Q3 2025 and bottomed at $93000.0 in Q3 2023.
- The 3-year median for Short term Debt is $11.8 million (2025), against an average of $9.2 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 21.33 Mn |
| Jun 30, 2025 | 11.80 Mn |
| Mar 31, 2025 | 12.72 Mn |
| Sep 30, 2023 | 93,000.00 |
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2019 | 2.71 Mn |